Six key changes to COPD-X guidelines
The Lung Foundation Australia has flagged changes to the COPD-X Guidelines following a new literature review, including:
- Long-acting muscarinic antagonist (LAMA) agents are similarly effective in preventing moderate-to-severe and severe COPD exacerbations. However tiotropium dry powder inhaler is the only formulation which reduces severe exacerbations.
- Once-daily treatment with indacaterol via Breezhaler (150 μg) and tiotropium bromide via HandiHaler (18 μg) equally improve lung function in patients with severe COPD and a history of